Literature DB >> 21859271

Progress in the development of human parainfluenza virus vaccines.

Alexander C Schmidt1, Anne Schaap-Nutt, Emmalene J Bartlett, Henrick Schomacker, Jim Boonyaratanakornkit, Ruth A Karron, Peter L Collins.   

Abstract

In children under 5 years of age, human parainfluenza viruses (HPIVs) as a group are the second most common etiology of acute respiratory illness leading to hospitalization, surpassed only by respiratory syncytial virus but ahead of influenza viruses. Using reverse genetics systems for HPIV serotypes 1, 2 and 3 (HPIV1, 2 and 3), several live-attenuated HPIVs have been generated and evaluated as intranasal vaccines in adults and in children. Two vaccines against HPIV3 were found to be well tolerated, infectious and immunogenic in Phase I trials in HPIV3-seronegative infants and children and should progress to proof-of-concept trials. Vaccines against HPIV1 and HPIV2 are less advanced and have just entered pediatric trials.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21859271      PMCID： PMC3503243          DOI： 10.1586/ers.11.32

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN： 1747-6348            Impact factor:   3.772


  98 in total

Review 1.  Respiratory syncytial virus: reverse genetics and vaccine strategies.

Authors:  Peter L Collins; Brian R Murphy
Journal:  Virology       Date:  2002-05-10       Impact factor: 3.616

2.  Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.

Authors:  M K Spriggs; B R Murphy; G A Prince; R A Olmsted; P L Collins
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

3.  The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.

Authors:  Mario H Skiadopoulos; Joanne M Tatem; Sonja R Surman; Yvonne Mitcho; Shin Lu Wu; William R Elkins; Brian R Murphy
Journal:  Vaccine       Date:  2002-03-15       Impact factor: 3.641

Review 4.  Influence of maternal antibodies on neonatal immunization against respiratory viruses.

Authors:  J E Crowe
Journal:  Clin Infect Dis       Date:  2001-10-05       Impact factor: 9.079

5.  Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.

Authors:  B R Murphy; R A Olmsted; P L Collins; R M Chanock; G A Prince
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

6.  Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics.

Authors:  Jason T Newman; Sonja R Surman; Jeffrey M Riggs; Chris T Hansen; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  Virus Genes       Date:  2002       Impact factor: 2.332

7.  Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.

Authors:  Alexander C Schmidt; Daniel R Wenzke; Josephine M McAuliffe; Marisa St Claire; William R Elkins; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

8.  Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers.

Authors:  R B Belshe; F K Hissom
Journal:  J Med Virol       Date:  1982       Impact factor: 2.327

9.  Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children.

Authors:  W P Glezen; A L Frank; L H Taber; J A Kasel
Journal:  J Infect Dis       Date:  1984-12       Impact factor: 5.226

10.  Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge.

Authors:  K L van Wyke Coelingh; C C Winter; E L Tierney; W T London; B R Murphy
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226
View more
  43 in total

1.  Inflammasome Antagonism by Human Parainfluenza Virus Type 3 C Protein.

Authors:  Niraj K Shil; Swechha M Pokharel; Amiya K Banerjee; Michael Hoffman; Santanu Bose
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

Review 2.  Advances in Vaccines to Prevent Viral Respiratory Illnesses in Children.

Authors:  Aleisha J Anderson; Tom L Snelling; Hannah C Moore; Christopher C Blyth
Journal:  Paediatr Drugs       Date:  2017-12       Impact factor: 3.022

3.  Relationships among dissemination of primary parainfluenza virus infection in the respiratory tract, mucosal and peripheral immune responses, and protection from reinfection: a noninvasive bioluminescence-imaging study.

Authors:  Crystal W Burke; Mei Li; Julia L Hurwitz; Peter Vogel; Charles J Russell
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

Review 4.  Pathogenesis of acute respiratory illness caused by human parainfluenza viruses.

Authors:  Henrick Schomacker; Anne Schaap-Nutt; Peter L Collins; Alexander C Schmidt
Journal:  Curr Opin Virol       Date:  2012-03-03       Impact factor: 7.090

Review 5.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

6.  Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.

Authors:  Natalie Mackow; Emérito Amaro-Carambot; Bo Liang; Sonja Surman; Matthias Lingemann; Lijuan Yang; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

Review 7.  Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.

Authors:  Charles J Russell; Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2015-12-09       Impact factor: 5.217

8.  Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.

Authors:  Bo Liang; Shirin Munir; Emerito Amaro-Carambot; Sonja Surman; Natalie Mackow; Lijuan Yang; Ursula J Buchholz; Peter L Collins; Anne Schaap-Nutt
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

9.  A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.

Authors:  Bo Liang; Yumiko Matsuoka; Cyril Le Nouën; Xueqiao Liu; Richard Herbert; Joanna Swerczek; Celia Santos; Monica Paneru; Peter L Collins; Ursula J Buchholz; Shirin Munir
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

10.  Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.

Authors:  John N Mason; Husni Elbahesh; Charles J Russell
Journal:  J Virol       Date:  2013-03-20       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.